Hbm Holdings Ltd
HKEX:2142
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Hbm Holdings Ltd
HKEX:2142
|
HK |
|
B
|
Buryatzoloto PAO
MOEX:BRZL
|
RU |
|
DRB Holding Co Ltd
KRX:004840
|
KR |
|
P
|
Palantir Technologies Inc
XETRA:PTX
|
US |
|
Minor International PCL
OTC:MNILY
|
TH |
Hbm Holdings Ltd
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
HBM Holdings Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutics in the fields of immuno-oncology and immunology diseases. The Company’s products include batoclimab, mainly used for immune thrombocytopenia (ITP), graves’ ophthalmopathy (GO), myasthenia gravis (MG), neuromyelitis optica spectrum disorder (NMOSD); and tanfanercept, mainly used for dry eye disease (DED). In addition, the Company researches and develops immuno-oncology portfolio, including internally developed next-generation immune-oncology assets targeting immune-desert, immune-excluded and inflamed tumors.
